Cellceutix Awarded Orphan Drug Designation for Retinoblastoma Treatment

The FDA has dubbed Cellceutix’s Kevetrin for eye cancer an orphan drug, a designation that reduces the cost of clinical development in rare diseases through grants and tax credits and often segues into speedier approval pathways.

The Massachusetts drugmaker is studying Kevetrin for the potential indication of retinoblastoma, a cancer of the retina that typically affects children under the age of 3.